← Back to Hypothesis | Reviews

⭐ Pericyte-targeted senolysis or senomorphic therapy will benefit only an early bi

Composite Score: 0.700 | Target: PDGFRB, CDKN2A, CDKN1A, BCL2, BCL2L1

Filter by type:

No structured reviews yet. Be the first to review this hypothesis!